- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - 

- Global, Pivotal Phase 3 Clinical Trial Ongoing to Evaluate Mavorixafor in Chronic Neutropenia -

BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company focused on improving the lives of people with rare hematology diseases, announced today that the European Commission (EC) has granted marketing authorization for XOLREMDI® (mavorixafor) capsules for the treatment of patients with WHIM syndrome in the European Union (EU). The approval follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). The marketing authorization was granted under exceptional circumstances, reflecting the ultra-rare nature of WHIM syndrome.